scholarly journals The Biological-Behavioral Effect Of Neuritin On Non-Small Cell Lung Cancer Vascular Endothelial Cells Via VEGFR And Notch1

2019 ◽  
Vol Volume 12 ◽  
pp. 9747-9755
Author(s):  
Qiao Zhang ◽  
Juan Zhang ◽  
Jian Zhang ◽  
Patiguli Aerxiding ◽  
Amina Quhai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Endothelial Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Vascular Endothelial Cells ◽  
Behavioral Effect ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Small Cell Lung

C0095 Circulating endothelial cells and microparticles as prognostic markers in advanced non-small-cell lung cancer

2012 ◽  
Vol 130 ◽  
pp. S200
Author(s):  
Tania Fleitas ◽  
Vicenta Martínez-Sales ◽  
Virtudes Vila ◽  
Edelmiro Reganon ◽  
David Mesado ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Endothelial Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Markers ◽  
Small Cell ◽  
Circulating Endothelial Cells ◽  
Small Cell Lung

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

2008 ◽  
Vol 26 (11) ◽  
pp. 1871-1878 ◽  
Author(s):  
Scott A. Laurie ◽  
Isabelle Gauthier ◽  
Andrew Arnold ◽  
Frances A. Shepherd ◽  
Peter M. Ellis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Antitumor Activity ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Small Cell Lung ◽  
Endothelial Growth Factor

PurposeAZD2171 is a potent inhibitor of vascular endothelial growth factor receptors that showed broad antitumor activity in preclinical models. Doses of up to 45 mg/d of AZD2171 are tolerable when administered alone. This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non–small-cell lung cancer.Patients and MethodsEligible patients received carboplatin targeted to an area under the concentration time curve of 6 mg · min/mL and paclitaxel 200 mg/m2, both on day 1 of a 3-week cycle; daily oral AZD2171 at either 30 mg or 45 mg commenced day 2 of cycle 1. Pharmacokinetics of all drugs were performed, and tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST).ResultsTwenty patients were enrolled. No dose-limiting toxicities were observed during cycle 1 at either dose. Fatigue, diarrhea, anorexia, and granulocytopenia were common; hypertension was manageable with a treatment algorithm designed for this protocol. No clinically significant drug-related bleeding was observed. At 45 mg/d, fatigue and diarrhea were increased, and headache and hoarseness were observed. Paclitaxel clearance decreased during cycle 2, but no other significant pharmacokinetic interactions were observed. After radiology review, confirmed responses were observed in nine patients (response rate, 45%; 95% CI, 23% to 68%); all but one enrolled patient showed evidence of tumor shrinkage, some with cavitation.ConclusionAZD2171 can be combined with standard doses of carboplatin/paclitaxel with encouraging antitumor activity. Toxicity is increased, but predictable and manageable.

Sign in / Sign up

Export Citation Format

Share Document